



Keyword Index

A			
abbott realtime hepatitis c virus assay	32:381	carbon monoxide	32:201
acoustic radiation force impulse imaging	32:362	carboxyhemoglobin	32:201
acute cholecystitis	32:518	carcinoembryonic antigen	32:545
acute pancreatitis associated lung injury	32:439	carcinoembryonic antigen-related cell adhesion molecule 1 (cd66a)	32:306
age	32:261, 327	cardiac output	32:55
alanine aminotransferase	32:10	cardiac rehabilitation	32:267
albuminuria	32:216	cardiometabolic index	32:620
aldosterone	32:614	cardioprotection	32:55
ang ii receptor type 1	32:439	carotid artery stenosis	32:86
angiotensin ii	32:439, 614	caspase-3	32:552
animal model	32:235	cecal ligation and puncture	32:452
animal study	32:68	chemotherapy	32:458
antegrade technique	32:403	cholecystokinin	32:113
antibiotics	32:255	chronic hepatitis b	32:559
anti-müllerian hormone	32:414	chronic liver disease	32:362, 397
antioxidants	32:391	circadian rhythm	32:227, 302
anti-thyroglobulin	32:427	clear cells	32:356
anti-thyroid peroxidase	32:427	clinicopathological findings	32:356
anxiety	32:103	clofarabine	32:227
asymmetric dimethyl arginine	32:414	coadministration	32:177
attention deficit hyperactivity disorder (adhd)	32:630	coal mixture workers	32:44
attention-deficit/hyperactivity disorder	32:103	colchicine	32:68
augmentation enterocystoplasty	32:323	color doppler imaging	32:38
aura	32:420	colorectal adenocarcinoma	32:196
autism spectrum disorder	32:103	core protein	32:487
B			
β-hcg	32:317	coronary artery disease	32:620
bacteremia	32:196	coronary heart disease	32:267
bacterial meningitis	32:501	cortisol	32:235
benzodiazepines	32:118	cumulative abnormal rate	32:44
biochemical recurrence	32:514	cumulative dust exposure	32:44
bioinformatics	32:165	cutaneous malignant melanoma	32:494
biologic graft	32:142	D	
biomarkers/exposure assessment	32:201	depression	32:103, 313
bispectral index	32:586	desflurane	32:32, 302
bk polyomavirus	32:152	dexamethasone	32:235, 614
bladder cancer	32:261, 327	dexmedetomidine	32:586
bladder tumor	32:147, 191	diabetic retinopathy	32:22, 475
body weight	32:185	diagnosis	32:27
breast	32:27	diuresis	32:614
bullying	32:103	docetaxel	32:458
C		dopamine	32:630
ca ²⁺ entry	32:55	doppler ultrasound	32:128
calcitonin	32:545	dorzolamide/timolol	32:38
		drug abuse	32:118

dtl	32:207	human bone marrow mesenchymal stem cells	32:1
dynamic stabilizer	32:207	human immunodeficiency virus	32:96, 526
dynesys	32:207	hypertension	32:177
E		hypoxia	32:292
echocardiography	32:572	hypoxia-inducible factor-1 α	32:348
ectopic pregnancy	32:317		
elderly	32:518	I	
electroencephalogram	32:446	immediate	32:147
ellipsoid zone	32:248	inducible nitric oxide synthase	32:348
endophenotype	32:630	injecting drug users	32:96, 526
endothelin-1	32:348	insertion torque	32:469
entecavir	32:10, 559	international index of erectile function-5	32:620
eplerenone	32:177	intraocular pressure	32:80
erectile dysfunction	32:91, 620	intraoperative neurophysiological monitoring	32:135
exercise capacity	32:267	ischemia	32:292
experimental epilepsy model	32:446	ischemia/reperfusion	32:339
extensor lag	32:624	ischemia-modified albumin	32:201
external limiting membrane	32:248	ischemic cardiomyopathy	32:241
extubation	32:80	isoflurane	32:302
F			
failure	32:317	K	
familial mediterranean fever	32:216	k_{dr} channels	32:607
finger tapping test (fft)	32:630	ki-67	32:494
flare-up phenomenon	32:458	kidney function	32:185
fluid responsiveness	32:373	kidney transplantation	32:152
fluorescence-activated cell sorting	32:487	kidney volume	32:185
fluoroquinolones	32:152	kmup-1	32:607
G			
gastric acid	32:255	L	
gastric cancer	32:68	lamivudine	32:10, 559
gastric emptying	32:113	laparoscopic cholecystectomy	32:32, 281
gene polymorphism	32:599	laparoscopy	32:403
gene profiles	32:165	laser coagulation	32:22
ghrelin	32:113	laser solid state	32:22
glaucoma	32:38	lc-ms/ms	32:118
gonadotropins	32:1	leuprorelin	32:567
goserelin	32:567	leydig cells	32:1
γ -protein-coupled receptor	32:55	liver	32:165, 339
graft-versus-host disease	32:142	liver cirrhosis	32:165
H		liver fibrosis	32:362
8-hydroxy guanine glycosylase	32:241	liver transplantation	32:128, 373
8-hydroxy-deoxyguanosine	32:241	living donor	32:185
<i>haemophilus influenzae</i>	32:501	low-compliant bladder	32:323
haplotypes analysis	32:552	lumbar intervertebral disc herniation	32:552
hashimoto's thyroiditis	32:427	lumbar spondylosis	32:207
head and neck neoplasm	32:407	lymphocyte	32:86
health related quality of life	32:427		
heart failure	32:614	M	
<i>helicobacter pylori</i>	32:255	macula	32:248
<i>helicobacter pylori</i> eradication	32:397	maternal serum afp	32:579
hepatectomy	32:281	melatonin	32:302, 391
hepatitis b virus	32:10, 96, 526	menstrual cycle	32:586
hepatitis c virus	32:381, 487	meta-analysis	32:599
hepatitis d virus	32:526	metabolic syndrome	32:267
hepatocellular carcinoma	32:306, 535	metastatic castration resistant prostate cancer	32:458
		methotrexate	32:317
		microalbuminuria	32:216
		microarray analysis	32:165
		microvessel density	32:74, 306
		migraine	32:420

minimally invasive surgical procedures	32:281	prostate cancer	32:74, 514,
morbidly adherent placenta	32:579		567
mouse	32:452	prostate-specific antigen	32:514, 567
N		proteinuria	32:185
<i>neisseria meningitidis</i>	32:501	proteogenomics	32:535
neostigmine	32:80	proton pump inhibitors	32:255
neurogenic bladder	32:323	pseudoexfoliation	32:38
neuroprotections sugammadex	32:292	pulmonary artery smooth muscle cells	32:607
neurotoxicology	32:201	pulmonary function	32:44
neutrophil-lymphocyte count ratio	32:507	pulmonary function indices	32:44
neutrophil-to-lymphocyte ratio	32:327		
new psychoactive substances	32:118		
nondominant hand	32:630		
O			
olfaction disorders	32:313	radical prostatectomy	32:403, 514
onco-proteogenomics	32:535	rapid virological response	32:381
oral cancer	32:391	rebaudioside a	32:446
oridonin	32:452	reconstructive surgical procedures	32:464
orthodontic microimplant	32:469	recurrence	32:261, 327
osseointegration	32:391	recurrent laryngeal nerve	32:135
osteoporosis	32:599	red cell distribution width	32:216
outcome	32:545	refractive error	32:475
ovarian reserve	32:414	relapse	32:559
oxidative stress	32:241	removal torque	32:469
P		renal cell carcinoma	32:16
pancreas	32:356	repeated prostate biopsy	32:74
partial cystectomy	32:191	resonance frequency	32:469
partial nephrectomy	32:16	ret proto-oncogene mutation	32:545
patch-clamp electrophysiology	32:607	retrobulbar ocular blood flow	32:38
pentoxifylline	32:339	retrograde technique	32:403
pentylenetetrazol	32:446	rhegmatogenous retinal detachment	32:248
percutaneous cholecystostomy	32:518	rho/rock pathway	32:439
percutaneous nephrolithotomy	32:507	rhoa/rock signaling	32:607
percutaneous release	32:624	robotic surgical procedures	32:281
percutaneous transhepatic portal vein stent	32:128	robotics	32:16
periodontitis	32:391		
pet scan	32:407		
pharmacokinetics	32:177, 227	S	
pituitary homeobox 1	32:494	salvage urethroplasty	32:464
pkg	32:55	sedation	32:586
placenta previa totalis	32:579	sepsis	32:452, 507
platelet	32:86	sevoflurane	32:302
platelet–lymphocyte ratio	32:91	skin transplantation	32:464
pleth variability index	32:373	small intestine submucosa	32:142
polycystic ovary syndrome	32:313	solid pseudopapillary neoplasm	32:356
polymorphism	32:241, 552	sporadic medullary thyroid carcinoma	32:545
portal vein stenosis	32:128	steatosis	32:306
portography	32:128	steroid injection	32:624
posttraumatic stress disorder	32:235	<i>streptococcus agalactiae</i>	32:501
primary dysmenorrhea	32:414	<i>streptococcus bovis</i>	32:196
primary restless legs syndrome	32:420	<i>streptococcus pneumoniae</i>	32:501
prognosis	32:494	stress	32:367
progression	32:261, 327	stress urinary incontinence	32:142
proinflammatory cytokine	32:452	suburethral slings	32:367
proliferation	32:68, 494	sugammadex	32:80
propofol	32:32	surgical margin	32:514
		susceptibility	32:552
		sustained virological response	32:381
		switch	32:559

systemic inflammation	32:216	trigger finger	32:624
systemic inflammatory response syndrome	32:507	tuberculosis	32:27
T			
tadalafil	32:339	unknown primary tumors	32:407
taiwan	32:96, 526	ureteral reimplantation	32:323
target-controlled infusion	32:32	urethral stricture	32:464
tartary buckwheat	32:177	urinary incontinence	32:367
telbivudine	32:10	urine proteomics	32:535
testosterone	32:1	urodynamics	32:367
thromboembolism	32:572	urolithiasis	32:507
thrombolytic agent	32:572	urothelial carcinoma	32:191
thyroidectomy	32:135	urothelial cell carcinoma	32:261
toxicity	32:227		
transcatheter arterial embolization	32:306	V	
transobturator tape	32:142	vascular endothelial growth factor	32:74, 348
transurethral resection	32:147	vesicoureteral reflux	32:323
treatment	32:27, 317	visual impairment	32:475
treatment outcome	32:255	vitamin d receptor	32:599